Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
2
×
boston blog main
boston top stories
cancer
2
×
genentech
life sciences
national blog main
national top stories
roche
2
×
san francisco blog main
avapritinib
blueprint medicines
cancer drugs
cancer immunotherapy
capmatinib
center for medicare and medicaid services
companion diagnostic
daniel o'day
deals
eli lilly
europe blog main
europe top stories
fda
foundation medicine
foundationone cdx
foundationone heme
gastrointestinal stromal tumors
indiana blog main
indiana top stories
life science
medullary thyroid cancer
new york blog main
non-small cell lung cancer
novartis
osimertinib
pralsetinib
rucaparib (rubraca)
san francisco top stories
selpercatinib
What
acquire
address
agreed
approval
approves
big
billion
blueprint
broad
cancer
carries
certain
confidence
designed
didn’t
drug
fda
foundation
gain
genentech
genetic
latest
medicine
medicines
momentum
morning
panels
pass
pay
pays
picked
profiling
recently
redux
remaining
rest
ret
roche
share
signature
Language
unset
Current search:
boston
×
cancer
×
roche
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
5 years ago
In a Genentech Redux, Roche Pays $2.4B for Rest of Foundation Medicine